LitAlert ~~ GeneLit.com

Phylogenetic Analysis IDs Subset of De Novo Tumors Unrelated to Primary DCIS.
Ray T.
GenomeWeb. Disease Areas. Cancer. 2022 Apr 11.

Conference report
Source abstract

Some Recurrent DCIS Breast Tumors are Actually New Lesions.
[No author given]
Inside Precision Medicine. Topics. Oncology. 2022 Apr 11.

Conference report
Free Full Text

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
Cheng Z, Mirza H, Ennis DP, Smith P, Morrill Gavarró L, Sokota C, Giannone G, Goranova T, Bradley T, Piskorz A, Lockley M; BriTROC-1 Investigators, Kaur B, Singh N, Tookman LA, Krell J, McDermott J, Macintyre G, Markowetz F, Brenton JD, McNeish IA.
Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643. Epub ahead of print.

Free Full Text (PDF)

An Exposure-Response Model with Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
Stodtmann S, Eckert D, Joshi R, Nuthalapati S, Ratajczak CK, Menon R, Mensing S, Xiong H.
J Clin Pharmacol. 2022 Apr 10. doi: 10.1002/jcph.2061. Epub ahead of print.

Identifier: NCT02163694: A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. (ClinicalTrials.gov)

Importance of Early Next-Generation Sequencing in Microsatellite Unstable Colon Cancer With a High Tumor Mutation Burden.
Ashish S, Raj M.
Cureus. 2022 Mar 6;14(3):e22894. doi: 10.7759/cureus.22894.

PMID: 35399448
PubMed abstract

Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
Anzellini D, Arcangeli G, Del Bianco S.
Cancer Diagn Progn. 2022 Jan 3;2(1):84-86. doi: 10.21873/cdp.10080.

PMID: 35400012
PubMed abstract